Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report

What is known and objective Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). Warfarin has many drug interactions, but no interactions with favipiravir have been reported. Case summary Our patient was taking warfarin for deep vein thrombosis. The international normalized ratio (INR) was stable (1.65 to 2.0); however, it increased to 4.63 after administering favipiravir. The patient had no other factors justifying this change. What is new and conclusion Favipiravir and warfarin might have previously unidentified drug interactions that elevated the INR. Therefore, INR must be closely monitored when they are concomitantly administered in COVID-19 patients.

Automated summary

There might be previously unidentified drug interactions between Favipiravir and warfarin that can elevate the INR, so close monitoring of the INR is necessary when they are co-administered in COVID-19 patients.